Post Profile






Rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer

(European Society for Medical Oncology) Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported today at the ESMO 2017 Congress in Madrid.
read more

share

Related Posts


ICON8 trial reaffirms standard dosing in ovarian cancer chemo

Health : EurekAlert: Health

(European Society for Medical Oncology) European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of th...

LORELEI: Taselisib boosts breast tumor shrinkage

Health : EurekAlert: Health

(European Society for Medical Oncology) Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) accord...

Pembrolizumab: promising response rate in pretreated metastatic gastric cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Pembrolizumab has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented today at the ES...

Patients with high risk prostate cancer may benefit 'equally' from two new treatments

Health : EurekAlert: Health

(European Society for Medical Oncology) Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO...

New data confirms superiority of docetaxel based triplet therapy in gastric cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial prese...

Comments


Copyright © 2016 Regator, LLC